![]() |
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Received for publication October 3, 2005.
Revised March 1, 2006.
Accepted for publication March 2, 2006.
B kinase-2 independent and dependent
inflammation in airway disease models: relevance of IKK-
2 inhibition to the clinic
NF-
B is a transcription factor believed to be
central in the expression of numerous
inflammatory genes and the pathogenesis of many
respiratory diseases. We have
previously demonstrated increased NF-
B pathway
activation in a steroid-sensitive
animal model of LPS-driven airway inflammation.
Interestingly, this phenomenon
was not observed in a steroid-insensitive model of
elastase-induced inflammation in
the rat. The aim of this study was to gather further
evidence to suggest that these
similar profiles of neutrophilic inflammation can be NF-
B-dependent or -
independent by determining the impact of an I
B
kinase-2 (IKK-2) inhibitor, TPCA-
1. In the LPS model TPCA-1 blocked the increase in NF-
B:DNA binding, a marker
of NF-
B pathway activation. This inhibition was
associated with a reduction in
inflammatory mediator release (TNF
/IL-l
/MMP-9) and
lung inflammatory cell
burden (neutrophilia/eosinophilia); data paralleled with
a steroid and in human cell
based assays. In the elastase-driven inflammation model,
in which our group has
previously failed to measure an increase in NF-
B:DNA binding, neither TPCA-1,
nor the steroid, impacted on mediator release (IL-1
/MMP-
9) or cellular burden
(neutrophilia/lymphomononuclear cells). This is the
first study examining the effect of
an IKK-2 inhibitor in well validated models which mimic
aspects of the inflammatory
lesion evident in diseases such as COPD. In conclusion
we have demonstrated that
animal models with similar profiles of airway
inflammation can be IKK-2
inhibitor/steroid sensitive or insensitive. If both
profiles of inflammation exist in the
clinic, then this finding is extremely exciting and may
lead to greater understanding of
disease pathology and the discovery of novel anti-
inflammatory targets.
Key words:
NFkappaB, Regulation of gene expression, Leukocytes/Mast cells
This article has been cited by other articles:
![]() |
S. J. Tudhope, M. C. Catley, P. S. Fenwick, R. E. K. Russell, W. L. Rumsey, R. Newton, P. J. Barnes, and L. E. Donnelly The Role of I{kappa}B Kinase 2, but Not Activation of NF-{kappa}B, in the Release of CXCR3 Ligands from IFN-{gamma}-Stimulated Human Bronchial Epithelial Cells J. Immunol., November 1, 2007; 179(9): 6237 - 6245. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Newton, N. S. Holden, M. C. Catley, W. Oyelusi, R. Leigh, D. Proud, and P. J. Barnes Repression of Inflammatory Gene Expression in Human Pulmonary Epithelial Cells by Small-Molecule I{kappa}B Kinase Inhibitors J. Pharmacol. Exp. Ther., May 1, 2007; 321(2): 734 - 742. [Abstract] [Full Text] [PDF] |
||||